<ul>
<li><strong>新的研究顯示，29-42 歲的人羣比其他年齡組更可能錯過宮頸篩查。1</strong></li>
<li><strong>幾乎三分之一的受訪歐洲千禧一代符合常規宮頸篩查資格的人推遲或跳過了他們的預約。1</strong></li>
<li><strong>宮頸癌是最可預防的癌症之一，幾乎所有病例都可以通過疫苗接種和定期篩查來避免。2</strong></li>
</ul>
<p>, /PRNewswire/ -- 羅氏（SIX: RO, ROG; OTCQX: RHHBY）今天宣佈研究結果顯示，31% 的符合條件的千禧一代推遲或錯過了他們的宮頸篩查預約，比所有年齡組的平均水平高出 27%。這些發現來自於羅氏委託並由 GWI 在六個歐洲國家進行的對 5,518 名 16-64 歲互聯網用户的調查。1</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2339048/Roche_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2339048/Roche_Logo.jpg"/></p>
<p>儘管在許多國家篩查服務廣泛免費或大幅補貼，但對於受訪的千禧一代而言，特定的挑戰使得獲取常規宮頸篩查變得困難。除了對疼痛、尷尬或與篩查相關的污名的恐懼外，研究還揭示，千禧一代在平衡職業、照顧責任和人際關係方面面臨特別的挑戰。這些重疊的承諾似乎將宮頸篩查推到了他們優先事項的底部，導致錯過或延遲預約的比例高於其他羣體。</p>
<p>&#34;千禧一代常被稱為 ‘擁有一切的世代’，在職業、照顧和社會期望之間忙碌。然而，他們往往把自己放在最後，&#34;羅氏診斷的健康政策與外部事務副總裁 Joanna Sickler 表示。&#34;研究顯示，千禧一代在優先考慮宮頸篩查方面明顯不足，原因是情感、後勤和社會壓力的混合。設計像自我採樣這樣的解決方案，使篩查能夠融入他們的現實中至關重要。這不僅重要，更是拯救生命的必要。&#34;</p>
<p>這些發現突顯了針對千禧一代面臨的障礙的實用、量身定製的干預措施的重要性。評論結果時，卡迪夫大學的 Daniel Kelly OBE 教授及歐洲癌症組織 HPV 和乙型肝炎行動網絡的共同主席表示：&#34;醫療系統必須發展，以適應女性的生活方式，提供靈活、以人為本的篩查選項和疫苗接種機會，同時促進開放對話和社區參與，使宮頸健康成為共同責任。&#34;</p>
<p>恐懼仍然是宮頸篩查出席的最大障礙。30% 的女性將恐懼視為錯過或延遲預約的主要原因，主要是由於對不適、疼痛或潛在結果的焦慮。調查還發現，職業承諾和工作場所的要求是一個主要因素，也是所有參與者的第二大障礙。高收入者（市場中收入範圍的前 1/3）比平均水平更可能推遲預約，27% 的這一羣體將工作場所的要求作為推遲的原因。推遲或取消篩查預約的千禧一代比普通人羣更可能（20%）表示，工作場所的靈活性和鼓勵會幫助他們優先考慮宮頸篩查。</p>
<p>照顧責任增加了複雜性，尤其是對於父母而言。對於許多人來説，家庭生活的需求優先於個人健康，27% 的受訪父母表示他們推遲或取消了宮頸篩查預約。</p>
<p>這些挑戰因缺乏對宮頸篩查的認識和討論而加劇，調查中有一半女性認為沒有支持或補貼醫療預約的計劃。此外，近 50% 的受訪者，包括 43% 的千禧一代，承認他們從未與任何人談論過宮頸篩查，突顯出一種普遍的文化不適，使許多人缺乏優先考慮篩查所需的情感支持或鼓勵。</p>
<p>實用和情感支持是提高出席率的關鍵。在推遲篩查的千禧一代中，12% 的人認為旅行或兒童照顧的幫助是一個重要的動機，而 19% 的人表示，工作場所的更大靈活性和僱主的鼓勵將幫助他們優先考慮預約。情感支持也起着作用，10% 的人表示，如果得到家人、朋友或同事的鼓勵，他們更可能參加。</p>
<p><strong>宮頸癌：只有我們所有人才能結束</strong></p>
<p>每年，宮頸癌在全球影響超過 60 萬名女性，2 然而幾乎所有病例都可以通過疫苗接種、早期檢測和前癌症的治療來預防。2 在羅氏診斷，我們致力於通過集體行動消除宮頸癌。我們的活動 “宮頸癌：只有我們所有人才能結束” 專注於減少獲取障礙，正常化關於宮頸健康的對話，並使更多符合條件的人能夠參加常規篩查。</p>
<p>羅氏正在與醫療系統、政府和社區合作，提供靈活的篩查選項，如自我採樣、包容性教育和關於早期檢測重要性的清晰溝通。我們可以共同幫助提高出席率，賦予個人採取行動保護健康的能力，並防止宮頸癌奪去更多生命。消除宮頸癌始於我們所有人。</p>
<p>欲瞭解更多信息，請訪問：https://roche.com/stories/cervical-cancer-it-only-ends-with-all-of-us</p>
<p><strong>關於羅氏</strong> 羅氏成立於 1896 年，總部位於瑞士巴塞爾，是最早的工業品牌藥物製造商之一，現已發展成為全球最大的生物技術公司和體外診斷領域的全球領導者。公司追求科學卓越，致力於發現和開發改善和拯救全球人民生命的藥物和診斷工具。我們是個性化醫療的先驅，旨在進一步改變醫療服務的交付方式，以產生更大的影響。為了為每個人提供最佳護理，我們與許多利益相關者合作，將我們的診斷和製藥優勢與臨牀實踐中的數據洞察相結合。</p>
<p>羅氏在追求長期視角的努力得到了認可，連續第十五年被道瓊斯可持續發展指數評選為製藥行業最可持續的公司之一。這一榮譽也反映了我們與每個國家的地方合作伙伴共同改善醫療服務可及性的努力。</p>
<p>美國的基因泰克是羅氏集團的全資成員。羅氏是日本中外製藥的主要股東。</p>
<p>欲瞭解更多信息，請訪問 www.roche.com。</p>
<p>本發佈中使用或提及的所有商標均受法律保護。</p>
<p>[1] GWI – 羅氏。2025 年宮頸癌歐洲研究。</p>
<p>[2] 世界衞生組織。宮頸癌事實表。可在以下網址獲取：https://www.who.int/health-topics/cervical-cancer#tab=tab_1</p>
<p>[3] 疾病控制與預防中心，HPV 引起的癌症。可在以下網址獲取：https://www.cdc.gov/hpv/about/cancers-caused-by-hpv.html</p>
<p><strong>羅氏診斷傳播</strong></p>
<p><strong>凱瑟琳·阿格爾</strong> 羅氏診斷高級傳播業務合作伙伴</p>
<p>kathryn.ager@roche.com</p>
<p>電話：+44 07745 115046</p>
<p>來源：羅氏</p>

羅氏(ADR)

<p>一項由羅氏委託的調查顯示，31% 的 29 至 42 歲的歐洲千禧一代推遲或錯過了宮頸癌篩查，這一比例顯著高於其他年齡組。導致這一趨勢的因素包括對疼痛和尷尬的恐懼，以及在工作和照顧責任之間平衡的挑戰。調查結果強調了需要量身定製的干預措施，例如自我採樣選項，以提高篩查出席率。羅氏旨在通過集體行動和提高對定期篩查重要性的認識來消除宮頸癌</p>

<ul>
<li><strong>New research shows that people aged 29-42 are more likely to miss cervical screenings than any other age group.1</strong></li>
<li><strong>Almost one third of surveyed European millennials eligible for routine cervical screening have postponed or skipped their appointment.1</strong></li>
<li><strong>Cervical cancer is one of the most preventable cancers, with almost all cases avoidable through vaccination and regular screenings.2</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>新的研究顯示，29-42 歲的人羣比其他年齡組更可能錯過宮頸篩查。1</strong></li>
<li><strong>幾乎三分之一的受訪歐洲千禧一代符合常規宮頸篩查資格的人推遲或跳過了他們的預約。1</strong></li>
<li><strong>宮頸癌是最可預防的癌症之一，幾乎所有病例都可以通過疫苗接種和定期篩查來避免。2</strong></li>
</ul>
</div><p>, /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today research findings showing that 31% of eligible millennials have postponed or missed their cervical screening appointments – 27% higher than the average across all age groups. The findings come from a survey of 5,518 internet users aged 16-64 commissioned by Roche and conducted by GWI across six European countries.1</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 羅氏（SIX: RO, ROG; OTCQX: RHHBY）今天宣佈研究結果顯示，31% 的符合條件的千禧一代推遲或錯過了他們的宮頸篩查預約，比所有年齡組的平均水平高出 27%。這些發現來自於羅氏委託並由 GWI 在六個歐洲國家進行的對 5,518 名 16-64 歲互聯網用户的調查。1</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2339048/Roche_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2339048/Roche_Logo.jpg"/></p>
<p>Despite screening services being widely available free of charge or heavily subsidised in many countries, for the millennials surveyed, specific challenges make accessing routine cervical screening difficult. In addition to the well-documented fears reported over pain, embarrassment or stigma surrounding screenings,1 the research reveals that millennials face a particular challenge in balancing careers, caregiving responsibilities, and relationships. These overlapping commitments appear to push cervical screenings – which remain vital for detecting HPV, the cause of over 99% of cervical cancers3 – to the bottom of their priorities, resulting in higher rates of missed or delayed appointments compared to other groups.</p>
<div class="lb-trans"><p>儘管在許多國家篩查服務廣泛免費或大幅補貼，但對於受訪的千禧一代而言，特定的挑戰使得獲取常規宮頸篩查變得困難。除了對疼痛、尷尬或與篩查相關的污名的恐懼外，研究還揭示，千禧一代在平衡職業、照顧責任和人際關係方面面臨特別的挑戰。這些重疊的承諾似乎將宮頸篩查推到了他們優先事項的底部，導致錯過或延遲預約的比例高於其他羣體。</p>
</div><p>&#34;Millennials are often said to be the 'have it all generation,' juggling careers,caregiving, and societal expectations. Yet, they tend to put themselves last,&#34; said Joanna Sickler, Vice-President, Health Policy and External Affairs at Roche Diagnostics. &#34;The research shows that millennials are disproportionately failing to prioritise cervical screening, because of a mix of emotional, logistical, and societal pressures. It's critical to design solutions like self-sampling that allow screening to fit into their reality. It's not just important, it's essential to saving lives.&#34;</p>
<div class="lb-trans"><p>&#34;千禧一代常被稱為 ‘擁有一切的世代’，在職業、照顧和社會期望之間忙碌。然而，他們往往把自己放在最後，&#34;羅氏診斷的健康政策與外部事務副總裁 Joanna Sickler 表示。&#34;研究顯示，千禧一代在優先考慮宮頸篩查方面明顯不足，原因是情感、後勤和社會壓力的混合。設計像自我採樣這樣的解決方案，使篩查能夠融入他們的現實中至關重要。這不僅重要，更是拯救生命的必要。&#34;</p>
</div><p>The findings highlight the importance of practical, tailored interventions that address the barriers millennials face. Commenting on the results, Professor Daniel Kelly OBE, Cardiff University, and Co-Chair of the HPV and Hep B Action Network at the European Cancer Organisation said: &#34;Healthcare systems must evolve to meet women where and how they live offering flexible, person-centred screening options and access to vaccination while fostering open dialogue and community engagement that normalise cervical health as a shared responsibility.&#34;</p>
<div class="lb-trans"><p>這些發現突顯了針對千禧一代面臨的障礙的實用、量身定製的干預措施的重要性。評論結果時，卡迪夫大學的 Daniel Kelly OBE 教授及歐洲癌症組織 HPV 和乙型肝炎行動網絡的共同主席表示：&#34;醫療系統必須發展，以適應女性的生活方式，提供靈活、以人為本的篩查選項和疫苗接種機會，同時促進開放對話和社區參與，使宮頸健康成為共同責任。&#34;</p>
</div><p>Fear remains the biggest barrier to cervical screening attendance. Thirty percent of all women cite fear as the primary reason for missing or delaying their appointments, driven by anxiety about discomfort, pain, or the potential results. The survey also found that professional commitments and workplace demands are a major factor, and the second-largest barrier for all participants. High-income earners (top third of income ranges across markets) are 22% more likely than average to delay appointments, and 27% of this group cite workplace demands as the reason for postponement. Millennials who delayed or cancelled screening appointments are 20% more likely than the general population to say that greater workplace flexibility and encouragement would help themprioritise cervical screenings.</p>
<div class="lb-trans"><p>恐懼仍然是宮頸篩查出席的最大障礙。30% 的女性將恐懼視為錯過或延遲預約的主要原因，主要是由於對不適、疼痛或潛在結果的焦慮。調查還發現，職業承諾和工作場所的要求是一個主要因素，也是所有參與者的第二大障礙。高收入者（市場中收入範圍的前 1/3）比平均水平更可能推遲預約，27% 的這一羣體將工作場所的要求作為推遲的原因。推遲或取消篩查預約的千禧一代比普通人羣更可能（20%）表示，工作場所的靈活性和鼓勵會幫助他們優先考慮宮頸篩查。</p>
</div><p>Caregiving responsibilities add another layer of complexity, particularly for parents. For many, the demands of family life take priority over personal health, with 27% of parents surveyed reported they had delayed or cancelled cervical screening appointments.</p>
<div class="lb-trans"><p>照顧責任增加了複雜性，尤其是對於父母而言。對於許多人來説，家庭生活的需求優先於個人健康，27% 的受訪父母表示他們推遲或取消了宮頸篩查預約。</p>
</div><p>These challenges are compounded by a lack of awareness and discussion around cervical screening, with half of women surveyed believing there are no schemes to support orsubsidise healthcare appointments. Additionally, nearly 50% of respondents, including 43% of millennials, admitted they had never spoken to anyone about cervical screening, highlighting a pervasive cultural discomfort that leaves many without the emotional support or encouragement needed to prioritise screenings.</p>
<div class="lb-trans"><p>這些挑戰因缺乏對宮頸篩查的認識和討論而加劇，調查中有一半女性認為沒有支持或補貼醫療預約的計劃。此外，近 50% 的受訪者，包括 43% 的千禧一代，承認他們從未與任何人談論過宮頸篩查，突顯出一種普遍的文化不適，使許多人缺乏優先考慮篩查所需的情感支持或鼓勵。</p>
</div><p>Practical and emotional support are key to improving attendance rates. Among millennials who postponed their screenings, 12% identified assistance with travel or childcare as a significant motivator, while 19% said greater workplace flexibility and encouragement from employers would help them prioritise their appointments. Emotional support also plays a role, with 10% saying they would be more likely to attend if encouraged by family, friends, or colleagues.</p>
<div class="lb-trans"><p>實用和情感支持是提高出席率的關鍵。在推遲篩查的千禧一代中，12% 的人認為旅行或兒童照顧的幫助是一個重要的動機，而 19% 的人表示，工作場所的更大靈活性和僱主的鼓勵將幫助他們優先考慮預約。情感支持也起着作用，10% 的人表示，如果得到家人、朋友或同事的鼓勵，他們更可能參加。</p>
</div><p><strong>Cervical cancer: it only ends with all of us</strong></p>
<div class="lb-trans"><p><strong>宮頸癌：只有我們所有人才能結束</strong></p>
</div><p>Every year, cervical cancer affects more than 600,000 women globally,2 yet it is preventable in almost all cases through vaccination, early detection, and treatment of precancers.2 At Roche Diagnostics, we are committed to the elimination of cervical cancer through collective action. Our campaign, Cervical cancer: it only ends with all of us, focuses on reducing barriers to access, normalising conversations about cervical health, and enabling more eligible individuals to attend their routine screenings.</p>
<div class="lb-trans"><p>每年，宮頸癌在全球影響超過 60 萬名女性，2 然而幾乎所有病例都可以通過疫苗接種、早期檢測和前癌症的治療來預防。2 在羅氏診斷，我們致力於通過集體行動消除宮頸癌。我們的活動 “宮頸癌：只有我們所有人才能結束” 專注於減少獲取障礙，正常化關於宮頸健康的對話，並使更多符合條件的人能夠參加常規篩查。</p>
</div><p>Roche is working alongside healthcare systems, governments, and communities to provide flexible screening options such as self-collection, inclusive education, and clear communication about the importance of early detection. Together, we can help improve attendance rates, empower individuals to take action for their health, and prevent cervical cancer from claiming more lives. Eliminating cervical cancer starts with all of us.</p>
<div class="lb-trans"><p>羅氏正在與醫療系統、政府和社區合作，提供靈活的篩查選項，如自我採樣、包容性教育和關於早期檢測重要性的清晰溝通。我們可以共同幫助提高出席率，賦予個人採取行動保護健康的能力，並防止宮頸癌奪去更多生命。消除宮頸癌始於我們所有人。</p>
</div><p>For more information, visit: https://roche.com/stories/cervical-cancer-it-only-ends-with-all-of-us</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問：https://roche.com/stories/cervical-cancer-it-only-ends-with-all-of-us</p>
</div><p><strong>About Roche</strong> Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.</p>
<div class="lb-trans"><p><strong>關於羅氏</strong> 羅氏成立於 1896 年，總部位於瑞士巴塞爾，是最早的工業品牌藥物製造商之一，現已發展成為全球最大的生物技術公司和體外診斷領域的全球領導者。公司追求科學卓越，致力於發現和開發改善和拯救全球人民生命的藥物和診斷工具。我們是個性化醫療的先驅，旨在進一步改變醫療服務的交付方式，以產生更大的影響。為了為每個人提供最佳護理，我們與許多利益相關者合作，將我們的診斷和製藥優勢與臨牀實踐中的數據洞察相結合。</p>
</div><p>In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.</p>
<div class="lb-trans"><p>羅氏在追求長期視角的努力得到了認可，連續第十五年被道瓊斯可持續發展指數評選為製藥行業最可持續的公司之一。這一榮譽也反映了我們與每個國家的地方合作伙伴共同改善醫療服務可及性的努力。</p>
</div><p>Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.</p>
<div class="lb-trans"><p>美國的基因泰克是羅氏集團的全資成員。羅氏是日本中外製藥的主要股東。</p>
</div><p>For more information, please visit www.roche.com.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.roche.com。</p>
</div><p>All trademarks used or mentioned in this release are protected by law.</p>
<div class="lb-trans"><p>本發佈中使用或提及的所有商標均受法律保護。</p>
</div><p>[1] GWI – Roche. Cervical Cancer Europe Study 2025.</p>
<div class="lb-trans"><p>[1] GWI – 羅氏。2025 年宮頸癌歐洲研究。</p>
</div><p>[2] World Health Organisation. Cervical Cancer Factsheet. Available at URL: https://www.who.int/health-topics/cervical-cancer#tab=tab_1</p>
<div class="lb-trans"><p>[2] 世界衞生組織。宮頸癌事實表。可在以下網址獲取：https://www.who.int/health-topics/cervical-cancer#tab=tab_1</p>
</div><p>[3] Centers for Disease Control, Cancers caused by HPV. Available at URL:https://www.cdc.gov/hpv/about/cancers-caused-by-hpv.html</p>
<div class="lb-trans"><p>[3] 疾病控制與預防中心，HPV 引起的癌症。可在以下網址獲取：https://www.cdc.gov/hpv/about/cancers-caused-by-hpv.html</p>
</div><p><strong>Roche Diagnostics Communications</strong></p>
<div class="lb-trans"><p><strong>羅氏診斷傳播</strong></p>
</div><p><strong>Kathryn Ager</strong> Senior Communications Business Partner, Roche Diagnostics</p>
<div class="lb-trans"><p><strong>凱瑟琳·阿格爾</strong> 羅氏診斷高級傳播業務合作伙伴</p>
</div><p>kathryn.ager@roche.com</p>
<div class="lb-trans"><p>kathryn.ager@roche.com</p>
</div><p>Phone: +44 07745 115046</p>
<div class="lb-trans"><p>電話：+44 07745 115046</p>
</div><p>SOURCE Roche</p>
<div class="lb-trans"><p>來源：羅氏</p>
</div>

羅氏委託的調查發現，千禧一代是最有可能錯過關鍵宮頸癌篩查的人羣 | 羅氏 (ADR) 股票新聞